India’s Caraco Pharma Wins U.S. Supreme Court To Market Generic
This article was originally published in PharmAsia News
Executive Summary
India’s Caraco Pharmaceuticals, the U.S. subsidiary of Sun Pharmaceutical Industries, won a unanimous U.S. Supreme Court verdict over Novo Nordisk.
India’s Caraco Pharmaceuticals, the U.S. subsidiary of Sun Pharmaceutical Industries, won a unanimous U.S. Supreme Court verdict when it denied an attempt by Novo Nordisk to block the Indian maker from marketing a generic of the diabetes drug Prondin (repaglinide). The court sided with Caraco, which argued it had the right to sue a branded drug maker claiming a patent that was so broad no generic would be able to get U.S. FDA approval. Caraco had the backing of the U.S. government, which opposed the Danish drug maker. (Click here for more
)
“U.S. Top Court Rules For Generic Drug Maker On Patent” – Reuters (4/17/12)